[go: up one dir, main page]

WO2012037547A3 - Methods and compositions for inhibiting autophagy for the treatment of fibrosis - Google Patents

Methods and compositions for inhibiting autophagy for the treatment of fibrosis Download PDF

Info

Publication number
WO2012037547A3
WO2012037547A3 PCT/US2011/052128 US2011052128W WO2012037547A3 WO 2012037547 A3 WO2012037547 A3 WO 2012037547A3 US 2011052128 W US2011052128 W US 2011052128W WO 2012037547 A3 WO2012037547 A3 WO 2012037547A3
Authority
WO
WIPO (PCT)
Prior art keywords
fibrosis
treatment
methods
compositions
inhibiting autophagy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/052128
Other languages
French (fr)
Other versions
WO2012037547A2 (en
Inventor
Scott L. Friedman
Zahra Ghiassi-Nejad
Virginia Hernandez-Gea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Mount Sinai School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai School of Medicine filed Critical Mount Sinai School of Medicine
Priority to EP11826075.1A priority Critical patent/EP2616082A2/en
Publication of WO2012037547A2 publication Critical patent/WO2012037547A2/en
Publication of WO2012037547A3 publication Critical patent/WO2012037547A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Provided are compositions and methods for the treatment of fibrosis. More particularly, autophagy inhibitors and methods of their use are provided for the treatment of fibrosis of liver, lung, kidney, and other tissues, and for the inhibition of stellate cell activation.
PCT/US2011/052128 2010-09-17 2011-09-19 Methods and compositions for inhibiting autophagy for the treatment of fibrosis Ceased WO2012037547A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11826075.1A EP2616082A2 (en) 2010-09-17 2011-09-19 Methods and compositions for inhibiting autophagy for the treatment of fibrosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38407610P 2010-09-17 2010-09-17
US61/384,076 2010-09-17

Publications (2)

Publication Number Publication Date
WO2012037547A2 WO2012037547A2 (en) 2012-03-22
WO2012037547A3 true WO2012037547A3 (en) 2012-06-28

Family

ID=45832287

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/052128 Ceased WO2012037547A2 (en) 2010-09-17 2011-09-19 Methods and compositions for inhibiting autophagy for the treatment of fibrosis

Country Status (2)

Country Link
EP (1) EP2616082A2 (en)
WO (1) WO2012037547A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013110608A1 (en) * 2013-09-26 2015-03-26 Florian Lang Substance for inhibiting tissue calcification, tissue fibrosis and age-associated diseases
CN103948601A (en) * 2014-05-06 2014-07-30 山东大学 Application of 3-methyladenine (3-MA) in preparing medicament for treating atherosclerosis and related diseases thereof
GB201512609D0 (en) 2015-07-17 2015-08-26 Royal Veterinary College The Methods
US10618939B2 (en) * 2016-06-29 2020-04-14 The Hong Kong Polytechnic University Hydrocarbon-stapled polypeptides for enhancement of endosome-lysosomal degradation
EP3620164A1 (en) * 2018-09-05 2020-03-11 Genoscience Pharma SAS Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases
CN115151561A (en) * 2019-09-25 2022-10-04 前沿药品公司 Targeted autophagy conjugates and methods
CN113134004A (en) * 2021-03-29 2021-07-20 中国医学科学院医学生物学研究所 Application of 3-methyladenine in preparation of drug for preventing acute pneumonia induced by pseudomonas aeruginosa
CN115960884B (en) * 2022-03-19 2024-03-12 三峡大学 Screening method for nucleic acid aptamer APT-Tan targeting activated hepatic stellate cells

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030203867A1 (en) * 2000-06-30 2003-10-30 Greenberg Arnold H. NIP3 family of proteins
WO2004035782A2 (en) * 2002-10-17 2004-04-29 Artemis Pharmaceuticals Gmbh Sirna mediated gene silencing in transgenic animals
US20040087016A1 (en) * 2000-05-12 2004-05-06 University Of Utah Research Foundation Compositions and methods for cell dedifferentiation and tissue regeneration
US20050009053A1 (en) * 2003-04-25 2005-01-13 Sebastian Boecker Fragmentation-based methods and systems for de novo sequencing
US20080194504A1 (en) * 2004-02-06 2008-08-14 Advanced Bionutrition Corporation Rna-Mediated Interference to Control Disease in Terrestrial and Aquaculture Animals
WO2009065090A2 (en) * 2007-11-14 2009-05-22 University Of Hawaii Pharmaceutical compositions for the treatment of conditions responsive to proteasome inhibition
US20100190749A1 (en) * 2008-11-03 2010-07-29 Pingda Ren Benzoxazole kinase inhibitors and methods of use

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087016A1 (en) * 2000-05-12 2004-05-06 University Of Utah Research Foundation Compositions and methods for cell dedifferentiation and tissue regeneration
US20030203867A1 (en) * 2000-06-30 2003-10-30 Greenberg Arnold H. NIP3 family of proteins
WO2004035782A2 (en) * 2002-10-17 2004-04-29 Artemis Pharmaceuticals Gmbh Sirna mediated gene silencing in transgenic animals
US20050009053A1 (en) * 2003-04-25 2005-01-13 Sebastian Boecker Fragmentation-based methods and systems for de novo sequencing
US20080194504A1 (en) * 2004-02-06 2008-08-14 Advanced Bionutrition Corporation Rna-Mediated Interference to Control Disease in Terrestrial and Aquaculture Animals
WO2009065090A2 (en) * 2007-11-14 2009-05-22 University Of Hawaii Pharmaceutical compositions for the treatment of conditions responsive to proteasome inhibition
US20100190749A1 (en) * 2008-11-03 2010-07-29 Pingda Ren Benzoxazole kinase inhibitors and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK 7 April 2005 (2005-04-07), retrieved from http://www.ncbi.nlm.nih.gov/nuccore/BV482162 accession no. V482162 *
DATABASE GENBANK retrieved from http://www.ncbi.nlm.nih.gov/nucgss/FH102951 accession no. H102951 *
LUCIANI ET AL.: "Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition.", NATURE CELL BIOLOGY, vol. 12, no. 9, September 2010 (2010-09-01), pages 863 - 875 *

Also Published As

Publication number Publication date
EP2616082A2 (en) 2013-07-24
WO2012037547A2 (en) 2012-03-22

Similar Documents

Publication Publication Date Title
WO2011032169A3 (en) Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
WO2012103059A3 (en) Bcl-2/bcl-xl inhibitors and therapeutic methods using the same
WO2012037547A3 (en) Methods and compositions for inhibiting autophagy for the treatment of fibrosis
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
IL222484A0 (en) Arginase inhibitor compounds, compositions comprising the same and uses thereof
WO2011002808A8 (en) Hcv protease inhibitors and uses thereof
WO2010120757A3 (en) Regeneration of tissue without cell transplantation
WO2011031896A3 (en) Pi3 kinase inhibitors and uses thereof
MY181898A (en) Heterocyclic compounds and uses thereof
WO2012158843A3 (en) Kinase inhibitors
WO2012087288A3 (en) Metal salt compositions
WO2011153157A3 (en) Benzoquinolone inhibitors of vmat2
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
WO2010132882A3 (en) Sublingual dexmedetomidine compositions and methods of use thereof
WO2012122383A3 (en) Pi3 kinase inhibitors and uses thereof
WO2012065019A3 (en) Combination comprising pyridopyrimidinone inhibitors of pi3k alpha
WO2009129267A3 (en) Small molecule inhibitors of the pleckstrin homology domain and methods for using same
WO2012040389A3 (en) Substituted bicyclic hcv inhibitors
WO2010033977A3 (en) Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
WO2009114703A3 (en) Combination therapy for the treatment of cancer
WO2013003298A3 (en) Inhibitors of pde10
WO2012065057A3 (en) Phosphatidylinositol 3-kinase inhibitors and methods of their use
IL223865A0 (en) Calcium salts of dihydrooroorotate dehydrogenase inhibitors, compositions comprising the same and uses thereof
WO2013023084A3 (en) Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells
WO2012073047A3 (en) Compositions and methods

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11826075

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011826075

Country of ref document: EP